Intravascular brachytherapy vs. drug-coated balloons for in-stent restenosis in patients with diabetes
In this first-ever comparison with 2-year follow-up in patients with diabetes, DCB was associated with similar MACE rates and cardiac mortality rates compared to IVB but demonstrated significantly lower target lesion failure. These findings suggest that while DCB offers superior efficacy for ISR treatment in patients with diabetes, careful patient selection is crucial, particularly considering diabetes-related comorbidities that strongly influence overall survival.
Authors
- Gal Sella (ORCID: https://orcid.org/0000-0003-0383-6471)
- Andrew Farach (ORCID: https://orcid.org/0000-0002-9982-4557)
- Elia El Hajj
- Omar Ayyad
- Alpesh Shah (ORCID: https://orcid.org/0000-0002-8600-6352)
- Albert E. Raizner (ORCID: https://orcid.org/0000-0001-9857-0519)
- Yueh-Yun Lin (ORCID: https://orcid.org/0000-0001-9034-7718)
- Muhammad Faraz Anwaar (ORCID: https://orcid.org/0000-0002-2361-3892)
- B TEH
- Gera Gandelman
- Devin Olek (ORCID: https://orcid.org/0000-0001-7006-8631)
- Mangesh Kritya (ORCID: https://orcid.org/0000-0002-5508-5107)
- Alex Blatt (ORCID: https://orcid.org/0000-0002-2168-5016)
- J G George
- Haitham Abu Khadija
- Neal S. Kleiman
- Anshuj Deva
- Joseph Elias
- Chloe Kharsa
Institutions
- Houston Methodist (US)
- Kaplan Medical Center (IL)
- Methodist Hospital (US)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fcvm.2025.1634096
- Primary Topic
- Coronary Interventions and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00